Trovagene Announces Second Quarter 2018 Highlights and Financial Results

SAN DIEGO, Aug. 3, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of leukemias, lymphomas and solid tumor cancers, today announced company highlights and financial results for the...